DOM-SOTALOL 160 MG
SOTALOL HYDROCHLORIDE : 160 MG · DIN 02238635 · DOMINION PHARMACAL
Health Canada status: CANCELLED POST MARKET
What is DOM-SOTALOL?
DOM-SOTALOL 160 MG contains SOTALOL HYDROCHLORIDE : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02238635, held by DOMINION PHARMACAL, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-May-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02238635 |
|---|---|
| Brand name | DOM-SOTALOL |
| Generic / active ingredient | SOTALOL HYDROCHLORIDE : 160 MG |
| Manufacturer | DOMINION PHARMACAL |
| Strength | 160 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AA07 SOTALOL |
| AHFS class | 28:36.20.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-May-2025 |
| Original market date | 1998-10-22 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C07AA07 SOTALOL. 3 of 55 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SOTALOL | 160 MG | TABLET | APOTEX INC | MARKETED | DIN 02167794 |
| APO-SOTALOL | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02210428 |
| PMS-SOTALOL - 80 MG | 80 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02238326 |
| AVA-SOTALOL | 160 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363682 |
| AVA-SOTALOL | 80 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363674 |
| CO SOTALOL | 160 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | DIN 02270633 |
| CO SOTALOL | 80 MG | TABLET | COBALT PHARMACEUTICALS COMPANY | CANCELLED POST MARKET | DIN 02270625 |
| DOM-SOTALOL | 80 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02238634 |
| FTP-SOTALOL | 160 MG | TABLET | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238615 |
| FTP-SOTALOL | 80 MG | TABLET | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238614 |
Who else supplies SOTALOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SOTALOL appears in 97 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.